Comparison of the rationality and safety of different doses of rivaroxaban in elderly patients with non valvular atrial fibrillation
Objective To investigate the clinical efficacy and safety of different doses of rivaroxaban in elderly patients with non valvular atrial fibrillation.Methods Sixty elderly patients with non valvular atrial fibrillation who were treated at the General Hospital of Pingxiang Mining Group Co.,Ltd.from June 2021 to December 2022 were randomly divided into three groups based on their admission numbers:A,B,and C,with 20 patients each.All patients were treated with rivaroxaban at doses of 20mg/d,15mg/d,and 10mg/d.Observe and compare the coagulation function,liver and kidney function,and adverse reactions of patients in groups A,B,and C before and after 6 months of treatment.Results After 6 months of treatment,the levels of serum D-dimer and antithrombin Ⅲ,and thrombin time in the three groups were significantly lower than before treatment(P＜0.05).There was no significant difference in serum D-dimer and antithrombin Ⅲ levels,and thrombin time among the three groups(P＞0.05).There was no significant difference in serum levels of aspartate aminotransferase,alanine aminotransferase,creatinine,and uric acid compared to before treatment(P＞0.05);A.There was no significant difference between the B and C groups(P＞0.05).During the treatment period,the incidence of adverse reactions in Group A was significantly higher than that in Group C(P＜0.05).Conclusions Three different doses of rivaroxaban can significantly improve coagulation function in elderly patients with non valvular atrial fibrillation,and have little impact on liver and kidney function.However,the incidence of adverse reactions is significantly lower and the safety is higher in patients using low-dose rivaroxaban.
Non valvular atrial fibrillationLevasabanCoagulation functionRenal functionLiver function
NETL
NSTL
万方数据
